159 related articles for article (PubMed ID: 21744716)
1. Likelihood of Brugada ECG pattern confirmed after propafenone administration for atrial fibrillation cardioversion.
Dragios TD; Manolis AG; Kyriakides ZS
Acta Cardiol; 2011 Jun; 66(3):399-400. PubMed ID: 21744716
[TBL] [Abstract][Full Text] [Related]
2. [Concealed Brugada syndrome that became apparent incidentally during atrial fibrillation therapy].
Yiğiner O; Kılıçaslan F; Tokatlı A; Işılak Z
Turk Kardiyol Dern Ars; 2011 Mar; 39(2):159-62. PubMed ID: 21430424
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study.
Bianconi L; Mennuni M; Lukic V; Castro A; Chieffi M; Santini M
J Am Coll Cardiol; 1996 Sep; 28(3):700-6. PubMed ID: 8772759
[TBL] [Abstract][Full Text] [Related]
4. Type 1 Brugada-Electrocardiogram: A Rare Presentation in a 57-Year-Old Woman with Paroxysmal Atrial Fibrillation Treated with a Therapeutic Dose of Propafenone.
Mowaswes M; Biton Y; Belhassen B
Isr Med Assoc J; 2021 Jul; 23(7):456-458. PubMed ID: 34251133
[No Abstract] [Full Text] [Related]
5. [Termination of paroxysm of atrial fibrillation conversion using oral propafenone after unsuccessful electrical cardioversion].
Kupriianova OG; Pavlov AV; Vaniev SB; Doshchitsin VL
Kardiologiia; 2012; 52(4):95-6. PubMed ID: 22839523
[No Abstract] [Full Text] [Related]
6. Brugada-like phenomenon, induced by intravenous propafenone, in a patient with idiopathic fascicular ventricular tachycardia.
Pino R; Sciortino G; Polizzi G
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):380-3. PubMed ID: 20414118
[No Abstract] [Full Text] [Related]
7. Is a drug-challenge test with propafenone adequate to exclude Brugada syndrome?
Yildiz BS; Gungor H; Gul I; Bilgin M; Zoghi M; Akilli A
Cardiovasc J Afr; 2013 Mar; 24(2):e4-6. PubMed ID: 23613002
[TBL] [Abstract][Full Text] [Related]
8. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Crijns HJ; Gosselink AT; Lie KI
Cardiovasc Drugs Ther; 1996 May; 10(2):145-52. PubMed ID: 8842506
[TBL] [Abstract][Full Text] [Related]
9. Transesophageal echocardiographic evidence of more pronounced left atrial stunning after chemical (propafenone) rather than electrical attempts at cardioversion from atrial fibrillation.
Antonielli E; Pizzuti A; Bassignana A; Tanga M; Baralis G; Rovere ME; Di Leo M
Am J Cardiol; 1999 Nov; 84(9):1092-6, A9-10. PubMed ID: 10569673
[TBL] [Abstract][Full Text] [Related]
10. Propafenone-induced Brugada-like ECG changes mistaken as acute myocardial infarction.
Chutani S; Imran N; Grubb B; Kanjwal Y
Emerg Med J; 2008 Feb; 25(2):117-8. PubMed ID: 18212157
[TBL] [Abstract][Full Text] [Related]
11. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
[TBL] [Abstract][Full Text] [Related]
12. Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report.
Karaca M; Dinckal MH
Acta Cardiol; 2006 Aug; 61(4):481-4. PubMed ID: 16970061
[TBL] [Abstract][Full Text] [Related]
13. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators.
Stroobandt R; Stiels B; Hoebrechts R
Am J Cardiol; 1997 Feb; 79(4):418-23. PubMed ID: 9052343
[TBL] [Abstract][Full Text] [Related]
14. Ventricular fibrillation storm in a child.
Einbinder T; Lowenthal A; Fogelman R
Europace; 2014 Nov; 16(11):1654. PubMed ID: 25344961
[No Abstract] [Full Text] [Related]
15. Atrial fibrillation, pharmacological cardioversion and topical ophthalmic beta-blocker use.
Patane' S; Marte F; Di Bella G; Pugliatti P
Int J Cardiol; 2008 Jun; 126(3):e43-6. PubMed ID: 17418438
[No Abstract] [Full Text] [Related]
16. Brugada-type ECG pattern in patients treated with oral flecainide for lone atrial fibrillation: is there any clinical implication?
Letsas KP; Weber R; Arentz T; Kalusche D
Hellenic J Cardiol; 2009; 50(4):338-9. PubMed ID: 19622506
[No Abstract] [Full Text] [Related]
17. Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome.
Pappone C; Brugada J; Vicedomini G; Ciconte G; Manguso F; Saviano M; Vitale R; Cuko A; Giannelli L; Calovic Z; Conti M; Pozzi P; Natalizia A; Crisà S; Borrelli V; Brugada R; Sarquella-Brugada G; Guazzi M; Frigiola A; Menicanti L; Santinelli V
Circ Arrhythm Electrophysiol; 2017 May; 10(5):e005053. PubMed ID: 28500178
[TBL] [Abstract][Full Text] [Related]
18. Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate.
Doni F; Staffiere E; Manfredi M; Piemonti C; Todd S; Rimondini A; Fiorentini C
Pacing Clin Electrophysiol; 1996 Nov; 19(11 Pt 2):1958-61. PubMed ID: 8945077
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone].
Peciuliene I; Lukoseviciūte A
Medicina (Kaunas); 2002; 38(12):1212-6. PubMed ID: 12552163
[TBL] [Abstract][Full Text] [Related]
20. [Idiopathic atrial fibrillation of recent onset and atrial stunning: the echocardiographic evidence after pharmacological cardioversion].
Ciolli A; De Sisti A; Montenero AS; Sanna T; Lo Sardo G; Palamara A
Cardiologia; 1998 Oct; 43(10):1077-82. PubMed ID: 9922572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
